A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Natarajan, Rama, Ph.D, F.A.H.A, F.A.S.N. Research Bookmark and Share

Rama Natarajan, Ph.D, F.A.H.A, F.A.S.N. Research

The major focus of our research is to determine the cellular and molecular mechanisms that play key roles in the development of diabetic vascular complications. We use genomic, transcriptomic and epigenomic approaches in cell culture, animal and clinical models to examine our hypothesis that accelerated vascular complications result from enhanced vascular and renal cell growth, and also monocyte activation due to altered expression of inflammatory cytokines, chemokines and lipids under diabetic conditions.
 
We are actively evaluating molecular mechanisms involved in the expression of pathological genes under diabetic conditions and in promoting metabolic memory. We have demonstrated the role of specific chromatin histone posttranslational modifications in the epigenetic regulation of inflammatory genes. We use epigenomic profiling approaches to map histone modifications, DNA methylation and binding of chromatin factors at diabetes-regulated genes with techniques such as Chromatin immunoprecipitation (ChIP) assays, ChIP-linked to microarrays, and ChIP-Sequencing. We have uncovered key epigenetic alterations under diabetic conditions in vitro, in vivo in diabetic mice, and in cells from diabetic patients, and shown relevance to the phenomenon of metabolic memory.
 
Another active area is the evaluation of specific microRNAs in regulating the expression of inflammatory and fibrotic genes under diabetic conditions. We are examining various mechanisms of microRNA regulation, performing expression profiling using RNA-sequencing, and studying how key microRNAs co-operate with each other in a circuit to amplify the effects of growth factors under diabetic conditions. To test the functional significance in the kidney, we are generating microRNA knockout mice and also evaluating novel modified inhibitors of specific microRNAs (antagomirs) on the progression of diabetic kidney disease in mouse models.
 

Rama Natarajan, Ph.D., Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rama Natarajan, Ph.D., F.A.H.A, F.A.S.N.
National Office Products Endowed Professor
626-256-HOPE (4673), ext. 62289
 
Marpadga A. Reddy, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63671
 
Feng Miao, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 65575
 
Mitsuo Kato, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63996
 
Kirti Bhatt, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65811
 
Nancy Castro, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64690
 
Ye Jia, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62289
 
Amy Leung, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62278
 
Jung-tak Park, M.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64809
 
Hang Yuan, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65817
 
Supriya Deschpande
Graduate Student
626-256-HOPE (4673), ext. 65835
 
Wen Jin
Graduate Student
626-256-HOPE (4673), ext. 65823
 
Linda Lanting, B.S.
Research Associate
626-256-HOPE (4673), ext. 64692
 
Mei Wang, M.S.
Research Associate
626-256-HOPE (4673), ext. 64676
 
Lingxiao Zhang, M.S.
Research Associate
626-256-HOPE (4673), ext. 65571
 
Nancy (Zhuo) Chen
Bioinformatics Specialist
656-256-HOPE (4673), ext. 65058
 

Natarajan, Rama, Ph.D, F.A.H.A, F.A.S.N. Research

Rama Natarajan, Ph.D, F.A.H.A, F.A.S.N. Research

The major focus of our research is to determine the cellular and molecular mechanisms that play key roles in the development of diabetic vascular complications. We use genomic, transcriptomic and epigenomic approaches in cell culture, animal and clinical models to examine our hypothesis that accelerated vascular complications result from enhanced vascular and renal cell growth, and also monocyte activation due to altered expression of inflammatory cytokines, chemokines and lipids under diabetic conditions.
 
We are actively evaluating molecular mechanisms involved in the expression of pathological genes under diabetic conditions and in promoting metabolic memory. We have demonstrated the role of specific chromatin histone posttranslational modifications in the epigenetic regulation of inflammatory genes. We use epigenomic profiling approaches to map histone modifications, DNA methylation and binding of chromatin factors at diabetes-regulated genes with techniques such as Chromatin immunoprecipitation (ChIP) assays, ChIP-linked to microarrays, and ChIP-Sequencing. We have uncovered key epigenetic alterations under diabetic conditions in vitro, in vivo in diabetic mice, and in cells from diabetic patients, and shown relevance to the phenomenon of metabolic memory.
 
Another active area is the evaluation of specific microRNAs in regulating the expression of inflammatory and fibrotic genes under diabetic conditions. We are examining various mechanisms of microRNA regulation, performing expression profiling using RNA-sequencing, and studying how key microRNAs co-operate with each other in a circuit to amplify the effects of growth factors under diabetic conditions. To test the functional significance in the kidney, we are generating microRNA knockout mice and also evaluating novel modified inhibitors of specific microRNAs (antagomirs) on the progression of diabetic kidney disease in mouse models.
 

Lab Members

Rama Natarajan, Ph.D., Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rama Natarajan, Ph.D., F.A.H.A, F.A.S.N.
National Office Products Endowed Professor
626-256-HOPE (4673), ext. 62289
 
Marpadga A. Reddy, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63671
 
Feng Miao, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 65575
 
Mitsuo Kato, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63996
 
Kirti Bhatt, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65811
 
Nancy Castro, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64690
 
Ye Jia, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62289
 
Amy Leung, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62278
 
Jung-tak Park, M.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64809
 
Hang Yuan, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65817
 
Supriya Deschpande
Graduate Student
626-256-HOPE (4673), ext. 65835
 
Wen Jin
Graduate Student
626-256-HOPE (4673), ext. 65823
 
Linda Lanting, B.S.
Research Associate
626-256-HOPE (4673), ext. 64692
 
Mei Wang, M.S.
Research Associate
626-256-HOPE (4673), ext. 64676
 
Lingxiao Zhang, M.S.
Research Associate
626-256-HOPE (4673), ext. 65571
 
Nancy (Zhuo) Chen
Bioinformatics Specialist
656-256-HOPE (4673), ext. 65058
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Ryan Chavira was a senior in high school when she began feeling sluggish, fatigued and, well, “down.” Trips to the doctor ended in “you’re fine” pronouncements; blood tests results showed nothing of real concern. But Chavira’s grandmother had passed away from ovarian cancer when she was in eig...
  • Brain tumors are exceptionally difficult to treat. They can be removed surgically, but individual cancer cells may have already spread elsewhere in the brain and can escape the effects of both radiation and chemotherapy. To prevent tumors from recurring, doctors need a way to find and stop those invasive cancer...
  • Breast cancer risk is personal; breast cancer risk assessment should be, too. To that end, City of Hope researchers have developed a starting point to help women (and their doctors) with a family history of the disease begin that risk assessment process. The result is an iPhone app, called BRISK, for Breast Can...
  • When it comes to breast cancer, women aren’t limited to getting screened and, if diagnosed, making appropriate treatment choices. They can also take a proactive stance in the fight against breast cancer by understanding key risk factors and practicing lifestyle habits that can help reduce their own breast...
  • Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on treating people with lymphoma, leukemia and myeloma, as well as other serious blood and bone...
  • Genetics, genes, genome, genetic risk … Such terms are becoming increasingly familiar to even nonresearchers as studies and information about the human make-up become more extensive and more critical. At City of Hope, these words have long been part of our vocabulary. Researchers and physicians are studyi...
  • Mammograms are currently the best method to detect breast cancer early, when it’s easier to treat and before it’s big enough to feel or cause symptoms. But recent mammogram screening guidelines may have left some women confused about when to undergo annual testing. Here Lusi Tumyan, M.D., chief of t...
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...